Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Open access
Anand, Sai Priya, Prévost, Jérémie, Nayrac, Manon, Beaudoin-Bussières, Guillaume, Benlarbi, Mehdi, Gasser, Romain, Brassard, Nathalie, Laumaea, Annemarie, Gong, Shang Yu, Bourassa, Catherine, Brunet-Ratnasingham, Elsa, Medjahed, Halima, Gendron-Lepage, Gabrielle, Goyette, Guillaume, Gokool, Laurie, Morrisseau, Chantal, Bégin, Philippe, Martel-Laferrière, Valérie, Tremblay, Cécile, Richard, Jonathan, Bazin, Renée, Duerr, Ralf, Kaufmann, Daniel E., Finzi, Andrés · 2021 · Cell Reports Medicine

Published version of a preprint

Abstract

Functional and lasting immune responses to the novel coronavirus (SARS-CoV-2) are currently under intense investigation as antibody titers in plasma have been shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we sought to determine the presence of SARS-CoV-2-specific memory B cells in COVID-19 convalescent patients. In this study, we report on the evolution of the overall humoral immune responses on 101 blood samples obtained from 32 COVID-19 convalescent patients between 16 and 233 days post-symptom onset. Our observations indicate that anti-Spike and anti-RBD IgM in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity in convalescent plasma declines rapidly compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which increase over time, and the number of IgG+ memory B cells which remain stable thereafter for up to 8 months after symptoms onset. With the recent approval of highly effective vaccines for COVID-19, data on the persistence of immune responses are of central importance. Even though overall circulating SARS-CoV-2 Spike-specific antibodies contract over time during convalescence, we demonstrate that RBD-specific B cells increase and persist up to 8 months post symptom onset. We also observe modest increases in RBD-specific IgG+ memory B cells and importantly, detectable IgG and sustained Fc-effector activity in plasma over the 8-month period. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for the prevention of secondary infections, vaccine efficacy and herd immunity against COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2021.100290

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 22

  1. Wheatley, 2021, Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19, Nat. Commun., 12, 1162, 10.1038/s41467-021-21444-5 · DOI · Paper page
  2. Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 · DOI · Paper page
  3. Perreault, 2020, Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset, Blood, 136, 2588, 10.1182/blood.2020008367 · DOI
  4. Prévost, 2020, Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike, Cell Rep. Med., 1, 100126, 10.1016/j.xcrm.2020.100126 · DOI · Paper page
  5. Pradenas, 2021, Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes, Med (N Y), 2, 313
  6. Chan, 2020, The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody, bioRxiv
  7. Anand, 2021, High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples, Transfusion, 10.1111/trf.16318 · DOI
  8. Rojas, 2020, Convalescent plasma in Covid-19: Possible mechanisms of action, Autoimmun. Rev., 19, 102554, 10.1016/j.autrev.2020.102554 · DOI · Paper page
  9. Li, 2020, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, 324, 460, 10.1001/jama.2020.10044 · DOI · Paper page
  10. Devasenapathy, 2020, Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis, CMAJ, 192, E745, 10.1503/cmaj.200642 · DOI
  11. Klingler, 2020, Role of IgM and IgA antibodies in the neutralization of SARS-CoV-2, medRxiv
  12. Gasser, 2021, Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2, Cell Rep., 34, 108790, 10.1016/j.celrep.2021.108790 · DOI
  13. Sterlin, 2021, IgA dominates the early neutralizing antibody response to SARS-CoV-2, Sci. Transl. Med., 13, eabd2223, 10.1126/scitranslmed.abd2223 · DOI · Paper page
  14. Chen, 2020, Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19, Signal Transduct. Target. Ther., 5, 180, 10.1038/s41392-020-00301-9 · DOI · Paper page
  15. Huang, 2020, A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity, Nat. Commun., 11, 4704, 10.1038/s41467-020-18450-4 · DOI · Paper page
  16. Abu-Raddad, 2021, SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks, medRxiv
  17. Natarajan, 2020, SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy, medRxiv
  18. Ullah, 2021, Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy, bioRxiv
  19. Brunet-Ratnasingham, 2021, Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality, medRxiv
  20. ter Meulen, 2006, Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med., 3, e237, 10.1371/journal.pmed.0030237 · DOI · Paper page
  21. Liu, 2013, The interferon-inducible MxB protein inhibits HIV-1 infection, Cell Host Microbe, 14, 398, 10.1016/j.chom.2013.08.015 · DOI · Paper page
  22. Lodge, 1997, The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells, EMBO J., 16, 695, 10.1093/emboj/16.4.695 · DOI · Paper page

Cited by

See all 175

Metadata

Authors
Anand, S. P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S. Y., Bourassa, C., Brunet-Ratnasingham, E., Medjahed, H., Gendron-Lepage, G., Goyette, G., Gokool, L., Morrisseau, C., Bégin, P., Martel-Laferrière, V., Tremblay, C., Richard, J., Bazin, R., Duerr, R., Kaufmann, D. E., & Finzi, A.
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2021-06
Volume
2
Issue
6
Pages
100290
ISSN
2666-3791 (ISSN-L)
OpenAlex
W3159965848
Cited by
175
References
24
FWCI
11.77
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • National Institutes of Health (R01 AI122953-05)
  • National Institute of Allergy and Infectious Diseases (ARP-4376)
  • American Foundation for Aging Research
  • Fondation du CHUM
  • CHU Sainte-Justine Foundation
  • Fonds de Recherche du Québec - Santé
  • Canada Foundation for Innovation (41027, RCHS0235 950-232424)
  • Mitacs
  • Canadian Institutes of Health Research (VR2-173203)
  • CIHR III (352417)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. https://app.cochat.ai/papers/10.1016/j.xcrm.2021.100290
The paper
Anand, S. P., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S. Y., Bourassa, C., Brunet-Ratnasingham, E., Medjahed, H., Gendron-Lepage, G., Goyette, G., Gokool, L., Morrisseau, C., Bégin, P., Martel-Laferrière, V., Tremblay, C., . . . Finzi, A. (2021). Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2021.100290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.